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Inactivation of TGFb receptors in stem cells
drives cutaneous squamous cell carcinoma
Patrizia Cammareri1,*, Aidan M. Rose2,*, David F. Vincent1,*, Jun Wang3, Ai Nagano3, Silvana Libertini1,
Rachel A. Ridgway1, Dimitris Athineos1, Philip J. Coates4, Angela McHugh2, Celine Pourreyron2,
Jasbani H.S. Dayal2, Jonas Larsson5, Simone Weidlich6, Lindsay C. Spender2, Gopal P. Sapkota6, Karin J. Purdie7,
Charlotte M. Proby2, Catherine A. Harwood7, Irene M. Leigh2,7, Hans Clevers8, Nick Barker9, Stefan Karlsson5,
Catrin Pritchard10, Richard Marais11, Claude Chelala3, Andrew P. South2,12, Owen J. Sansom1 & Gareth J. Inman2
Melanoma patients treated with oncogenic BRAF inhibitors can develop cutaneous squamous
cell carcinoma (cSCC) within weeks of treatment, driven by paradoxical RAS/RAF/MAPK
pathway activation. Here we identify frequent TGFBR1 and TGFBR2 mutations in human
vemurafenib-induced skin lesions and in sporadic cSCC. Functional analysis reveals these
mutations ablate canonical TGFb Smad signalling, which is localized to bulge stem cells in
both normal human and murine skin. MAPK pathway hyperactivation (through BrafV600E or
KrasG12D knockin) and TGFb signalling ablation (through Tgfbr1 deletion) in LGR5þ ve stem
cells enables rapid cSCC development in the mouse. Mutation of Tp53 (which is commonly
mutated in sporadic cSCC) coupled with Tgfbr1 deletion in LGR5þ ve cells also results in cSCC
development. These ﬁndings indicate that LGR5þ ve stem cells may act as cells of origin for
cSCC, and that RAS/RAF/MAPK pathway hyperactivation or Tp53 mutation, coupled with
loss of TGFb signalling, are driving events of skin tumorigenesis.
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T
he development of epithelial tumours is generally accepted
to take place over several years, involving the accumulation
of mutations that drive tumour progression1. However,
some tumours contain a relatively low mutation burden2 and
develop rapidly, without progression from benign intermediary
stages, suggesting a potential stem cell origin3. Data from murine
model systems illustrate a tumour’s ability to form from both
stem and differentiated cells. Within intestinal epithelium, loss of
Apc in the LGR5þ ve stem cell compartment leads to adenoma,
whereas tumours rarely form from differentiated cells4.
Conversely, we have shown that targeting Kras, in addition to
Apc, can de-differentiate intestinal villi and permit tumour
formation5. Thus, the tumour cell of origin remains unclear, as
does the standard model of progression from benign tumour to
malignant carcinoma.
Discord with the progression model is exempliﬁed in the skin,
which carries a high mutation burden6. Asymptomatic normal
skin carries frequent mutations in TP53 (refs 7,8) and NOTCH6,8.
Classic chemical carcinogenesis 7,12-Dimethylbenz[a]anthracene
(DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) experiments
demonstrate Hras mutations can lie dormant in the skin (without
the addition of TPA), at no obvious consequence to the tissue9.
Indeed even when Ras mutation is targeted to stem cell
compartments (for example, LRIG1þ ve cells or bulge stem
cells10,11), this does not lead to cancer unless there is a disruption
of tissue homeostasis through wounding. These ﬁndings support
the hypothesis that homeostasis within stem cell compartments
plays an important tumour suppressive role in highly organized
structures such as the skin.
We reasoned that, in the absence of wounding, mutations in
other oncogenic/tumour suppressor genes might facilitate rapid
skin tumorigenesis. Using targeted sequence analysis and whole-
exome sequencing (WES), we identify frequent mutation in both
transforming growth factor-b (TGFb) type 1 receptor (TGFBR1)
and TGFb type 2 receptor (TGFBR2) genes in human primary
cutaneous squamous cell carcinoma (cSCC) samples. IntOgen
mutation analysis reveals TGFb signalling as a pathway
signiﬁcantly altered by mutation and functional analysis of
several TGFb receptor mutants indicates that many of these
mutations result in loss of function. Pathway activation studies
reveal highly localized TGFb signalling in both normal human
and mouse hair follicle bulge stem cells. In murine skin, targeted
activation of the RAS/RAF/mitogen-activated protein kinase
(MAPK) pathway, coupled with deletion of Tgfbr1 in LGR5þ ve
stem cells, promotes rapid development of cSCC, which, in the
absence of wounding, may mimic the kinetics of tumour
induction in vemurafenib-induced cSCC. Combined Tp53 muta-
tion/inactivation coupled with Tgfbr1 loss in LGR5þ ve stem cells
also results in cSCC with longer latency, providing a model for
cSCC development without RAS activation.
Results
TGFBR1 and TGFBR2 are frequently mutated in human cSCC.
Cutaneous squamo-proliferative lesions (including keratoa-
canthomas and cSCC) arise in a signiﬁcant proportion of patients
treated with the type I RAF inhibitor vemurafenib. Such lesions
develop within a few weeks of treatment12,13. Targeted
sequencing has revealed that these lesions contain a high
frequency of activating mutations in HRAS6,12,13. Cutaneous
lesions isolated from patients treated with sorafenib (the
‘pan-RAF’ inhibitor) also harbour mutations in HRAS, TP53
and TGFBR1 (ref. 14). Employing targeted deep sequencing of 39
squamo-proliferative lesions from seven patients (including cSCC
and actinic keratosis (Supplementary Table 1) treated with
vemurafenib (using a percentage variance criterion of410%), we
identiﬁed frequent coding mutations in both TGFBR1 (8/39, 21%
of samples) and TGFBR2 (5/39, 13% of samples), revealing
mutation of TGFb receptors in 28% of lesions (Fig. 1a and
Supplementary Data 1). These mutational events were only
surpassed in frequency by mutations in NOTCH1/NOTCH2
(56%) and activating mutations of HRAS (38%). TP53 mutations
arose in 26% of lesions6 (Fig. 1a and Supplementary Data 2). In
contrast to NOTCH (using our mutational call cutoff, see
Methods), we did not detect any mutations in TGFb receptors
or HRAS in the normal or perilesional skin samples (n¼ 6 from 4
patients, 3 of which had lesions containing TGFb receptor
mutations). These ﬁndings imply that a combination of potential
mutational inactivation of TGFb signalling and activation of
HRAS may be important driving events in vemurafenib-induced
skin lesions and skin tumorigenesis.
We next sought to investigate whether loss of TGFb signalling
is a frequent event in sporadic cSCC. We employed targeted 454
pyrosequencing of TGFBR1 and TGFBR2 in 91 human primary
cSCC samples (Supplementary Table 2) and 21 human cell lines
derived from primary cSCC15, all of which were recently
sequenced for common genetic alterations6. Using a percentage
variance criterion of410%, we detected mutations of TGFBR1 in
22% and TGFBR2 in 30% of primary cSCC samples and 14% of
cell lines (Fig. 1b,c and Supplementary Data 3). Overall, mutation
of TGFb receptors occurred in 43% of primary cSCC samples.
These mutational events were only surpassed in frequency by
mutations in NOTCH1/2 (86%) and this time TP53 (63%)
(Fig. 1b, Supplementary Data 4 and ref. 6). In sporadic cSCC,
oncogenic activation of RAS only occurred in 9% of samples
(Fig. 1b, Supplementary Data 4 and ref. 6). We then sequenced
normal blood samples from eight patients with sporadic cSCC,
whose lesions harboured mutations in TGFb receptors
(Supplementary Data 3) and found no TGFb receptor
mutations. Next, we prospectively collected a further Dundee
cohort of seven primary cSCC samples with complementary
matched normal distant and perilesional skin (Supplementary
Table 3). This cohort demonstrated a comparable spectrum of
mutation in our selected gene panel and in both TGFb receptors
(Fig. 1d and Supplementary Data 5). TGFb receptor mutations
were again not identiﬁed in either distant or perilesional skin. To
assess the potential lesion-speciﬁc, non-germline signiﬁcance of
TGFb receptor mutations, we interrogated the pyrosequencing
analysis in depth from all of the samples containing normal
matched tissue (Supplementary Data 6). We observed only 8
variant reads out of 1,348 reads in total, in 4 out of 25 matched
normal sample reads. Three of these samples were from
perilesional skin and probably reﬂect rare contaminating
tumour cells. In comparison, we observed 237 variant reads out
of 1,340 reads in the tumour samples. Employing Fisher’s exact
two-sided tests to compare variant allele frequencies (VAFs) in
matched samples, we determined that 17/25 of the TGFb receptor
mutations reached tumour-speciﬁc VAF statistical signiﬁcance,
conﬁrming the lesion-speciﬁc, non-germline nature of these
mutations (Supplementary Data 6).
TGFBR1 and TGFBR2 mutations are driver events in human
cSCC. Next, we examined a further cohort of 30 primary cSCC
samples with matched normal tissue (Supplementary Table 4)
employing next-generation WES (see Methods) and interrogated
in detail NOTCH1, NOTCH2, TP53, CDKN2A, HRAS, KRAS,
NRAS, TGFBR1 and TGFBR2 genes for mutational and copy
number changes (Fig. 2a and Supplementary Data 7). We
observed alterations in all of these genes with a similar frequency
to that of our previous 454 pyrosequencing analysis. None of the
mutational events were found in the matched normal samples
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and all except two of these were statistically signiﬁcant (Fisher’s
exact t-test) (Supplementary Data 8). Importantly, we observed
changes in TGFBR1 in 30% of the samples and changes in
TGFBR2 in 40% of the samples with a combined alteration in 53%
of samples, conﬁrming a frequent alteration of TGFb receptor
genes in cSCC. Copy number analysis also revealed that loss of
heterozygosity occurred in both TGFBR1 and TGFBR2 genes
including in tumours with missense mutations in TGFBR2
(Fig. 2a and Supplementary Data 8). Somatic single nucleotide
variants (SNVs) of TGFb receptors were detected in 30% of our
samples consistent with our 454 pyrosequencing analysis and the
recent sequencing analyses of two North American cSCC cohorts,
which, when combined, detected TGFb receptor proteins altering
SNVs in 15.7% of samples16,17. Given the high mutational burden
of cSCC, it is probable that many mutations identiﬁed will be
passenger mutations with no functional consequence for
tumorigenesis. We investigated the potential functional conse-
quence of the mutations detected by WES employing MutsigCV18
and IntOgen analysis19. MutsigCV detected TP53, CDKN2A,
NOTCH1 and NOTCH2 as signiﬁcant drivers but no RAS genes
and IntOgen detected TP53, CDKN2A NOTCH1 and HRAS as
signiﬁcant drivers but did not identify NOTCH2, KRAS or NRAS
(Supplementary Data 9). Neither analysis detected TGFBR1
or TGFBR2 individually as signiﬁcant drivers (Supplementary
Data 9); however, IntOgen pathway analysis revealed TGFb
signalling as a signiﬁcantly altered signalling pathway
(Oncodrive-fm functional impact bias, functional mutation
bias19, P¼ 0.0019; Supplementary Data 10). We assessed the
clonality of our candidate driver genes using the ABSOLUTE
algorithm20. WES data were of sufﬁcient quality for 24/30 exomes
and ABSOLUTE analysis revealed purity and ploidy estimates
ranging from 0.2 to 0.73 and from 1.78 to 5.79, respectively
(Supplementary Data 11). ABSOLUTE clonality analysis
indicated that all NOTCH1, CDKN2A and RAS mutations were
clonal as were all bar one TP53, three NOTCH2 and one TGFBR1
mutation, which were subclonal (Fig. 2b,c and Supplementary
Data 12). Mutations present in nearly all tumour cells (clonal)
would suggest early events and therefore represent initiating
‘driver’ genes as appears to be the case here for NOTCH1,
NOTCH2, CDKN2A, HRAS, KRAS, TP53 and, importantly, both
TGFBR1 and TGBFR2.
Having established the probable driver event of mutation of
TGFBR1 and TGFBR2 in our WES data set, we extended this
analysis to include our samples assessed by targeted sequencing.
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Figure 1 | TGFb receptors are frequently mutated in vemurafenib-induced skin lesions and sporadic cSCC tumours.Mutation frequency, distribution and
relationship with pathological features of skin lesions isolated from vemurafenib-treated patients (n¼ 39) (a), sporadic cSCC (n¼91) (b), 21 cSCC cell lines
(RDEB, recessive dystrophic epidermolysis bullosa) (c); (a–c, adapted from ref. 6); 7 sporadic cSCC tumours (T) and normal distant/perilesional skin
samples (N) collected in Dundee (d). Mutation status for nine genes is indicated and the overall percentage mutation is shown on the left. Each column
represents a single case. Colours correspond to speciﬁc mutations as shown. Details of clinical parameters are included in Supplementary Tables 1–3 and
mutations are included in Supplementary Data 1–5.
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We ﬁrst calculated average percentage VAFs for our candidate
drivers and these ranged from 48.7% for CDKN2A to 20% for
TGFBR1 (Fig. 3a). TGFBR1 VAF was signiﬁcantly lower than that
of CDKN2A, TP53, HRAS, NOTCH1, TGFBR2 and NOTCH2 but
not KRAS and NRAS (Fig. 3a and Supplementary Data 13).
TGFBR2 VAF was only statistically signiﬁcantly lower than
CDKN2A and TP53 but equivalent to KRAS, NOTCH2 and NRAS
(Fig. 3a and Supplementary Data 13). The VAFs of the TGFb
receptors are of a similar range to those observed in other cSCC
driver genes. Ultraviolet light is the major oncogenic stimulus of
cSCC and the % of mutations conforming to an ultraviolet
signature (C-T or G-A transitions) of our candidate drivers ranged
from 79.7% in CDKN2A to 30.4% in HRAS (Fig. 3b), with
mutations in both TGFb receptor genes lying within this range.
VAFs were statistically signiﬁcantly higher for ultraviolet signature
mutations for NOTCH2, CDKN2A and TGFBR2 (Supplementary
Fig. 1a and Supplementary Data 14). If these candidate genes
represent potential driver genes then the mutational consequence
should be predicted to change protein function. We classiﬁed these
mutations as potentially damaging if they were predicted to be so
by at least two of the four mutation function prediction
programmes SIFT21, PolyPhen-2 (ref. 22), Provean23 and
Mutation Assessor24 or were a splice site or PTC mutation
(Fig. 3c). Damaging mutation rates ranged from 89% for TP53 to
53.5% for TGFBR1 (Fig. 3c and Supplementary Data 15–23) were
statistically signiﬁcantly higher for those with an ultraviolet
signature for NOTCH2, TGFBR2 and TP53 (Fig. 3d and
Supplementary Data 24), and damaging mutations had higher
VAFs for NOTCH2, CDKN2A, TGFBR2 and NOTCH1 (Supple-
mentary Fig. 1b and Supplementary Data 25). Together, our data
suggest thatB70% of TGFBR2 and 50% of TGFBR1mutations will
alter protein function with the potential to drive cSCC
development. In its entirety, our analysis conservatively estimates
functionally relevant TGFBR1 and TGFBR2 mutations in B10%
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Figure 2 | Target gene mutation and copy number and clonality analysis in 30 cSCC primary tumours analysed by WES. (a) Mutation frequency,
distribution and relationship with pathological features from 30 cSCC primary tumours. Mutation and copy number status (gain, loss and acquired
uniparental disomy) for nine genes is indicated and the overall percentage alteration is shown on the left. Each column represents a single case. Colours
correspond to speciﬁc mutations and copy number changes as shown. Split columns indicate where more than one mutation type is present in a single
case. Details of clinical parameters and mutations are included in Supplementary Table 4 and Supplementary Data 7. (b) ABSOLUTE clonality analysis of
potential driver genes of cSCC indicates that all nine genes are frequently clonal. (c) Cancer cell fraction clonality analysis indicates clonal and subclonal
mutations in the indicated tumours.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12493
4 NATURE COMMUNICATIONS | 7:12493 | DOI: 10.1038/ncomms12493 | www.nature.com/naturecommunications
vemurafenib-induced lesions
vemurafenib-induced lesions
TGFBR2
TGFBR1
%
 M
ut
at
io
ns
%
 M
ut
at
io
ns
%
 M
ut
at
io
ns
%
 V
AF
C44R
P45R
N95S
C96R
C102S
Sporadic cSCC
Extracellular domain
Transmembrane domain
Gs Domain
Domain of unknown function
Protein kinase domain
Isoform-2 variant
Missense Mutation
Nonsense Mutation
Sporadic cSCC
Damaging
CDKN2A TP53 HRAS NOTCH1 TGFBR2 KRAS NOTCH2 NRAS TGFBR1
Damaging
Non-damaging
Non-damaging
UV
Non-UV
TP
53
CD
KN
2A
TP
53
NO
TC
H2
NO
TC
H1
NR
AS
TG
FB
R2
KR
AS
TG
FB
R1
HR
AS
100
90
80
70
60
50
40
30
20
10
0
100
<0.001 0.008 0.026 0.109 0.147 0.210 0.337 0.458 0.786
90
80
70
60
50
40
30
20
10
0
100
90
80
***
TGFBR1 <0.001<0.001 <0.001 <0.001
0.001 0.049 0.475 0.602 0.548
0.266 0.01 0.571
0.302 0.436 0.016
0.016 –
–TGFBR2
***
** *
***
*** ** *
*** *
*
*
80
70
60
50
40
30
20
10
0
70
60
50
40
30
20
10
0
NOTCH2
N
on
-U
V UV UV UV UV UV UV UV UV UV
N
on
-U
V
N
on
-U
V
N
on
-U
V
N
on
-U
V
N
on
-U
V
N
on
-U
V
N
on
-U
V
N
on
-U
V
TGFBR2 TP53 TGFBR1 HRAS NOTCH1 KRAS CDKN2A NRASC
DK
N2
A
NR
AS
HR
AS
NO
TC
H1
TG
FB
R2
KR
AS
TG
FB
R1
NO
TC
H2
1 32 57 13 177 444 491 534 592
8 9
E107G
C109R C163Y
D166G
l208V R232W A257T
E308X
C38Y
D44G
N45S
K213E F216S
D51N
K108R
P159A
N150D
T175I
L207S
R237K
L278S
H283R
V299A
L305P
T309M
G312S
L313P
V373E
R377G
K397E
F408L V445I
K343E
R80X
P79S
172V
T113I*D76G
*I109V
*W277C *H331R
H39Y
F37S
N344D
W312X W347X
P392L
L379F
l322V
l400L
V412G
L452S
G445E
D471N
V478M
K513R
C558Y
E565G
*S474F
*C486R
*S320X
W369XN291D
T264I
K149R
S143P
I137T
A111V
R395K C419Y A556T
765432
1
1
1 2 3 4 5 6 7 8
33 115 192 269 326 377 419 463 503
a b
c d
e
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and B16% of samples, respectively, and therefore 20% of cSCC
samples could harbour damaging TGFb receptor mutations.
TGFb receptor mutation inactivates canonical Smad signalling.
Identiﬁed missense and nonsense mutations were found
throughout the coding exons of both TGFBR1 and TGFBR2,
occurring in the extracellular and kinase domains of each protein
(Fig. 3e). Structural analysis of the extracellular domains of
TGFBR1 (Supplementary Fig. 2) and TGFBR2 (Supplementary
Fig. 3) indicated mutations occur in, or in close proximity to,
highly conserved disulphide bonds, ligand interaction motifs and/
or receptor interaction motifs. These ﬁndings suggest signiﬁcant
potential for loss of function25,26.
TGFb signals via activation of a heterotetrameric complex of
TGFBR2:TGFBR1, resulting in TGFBR1-kinase driven carboxy-
terminal phosphorylation of SMAD2 and SMAD3 (ref. 27). Once
phosphorylated (PO4), SMAD2 and SMAD3 form hetero-
oligomeric complexes with the co-Smad SMAD4 accumulate in
the nucleus and regulate gene expression of hundreds of target
genes28,29. Activity of SMAD-dependent reporter gene constructs
and steady-state levels of SMAD2/3 C-terminal phosphorylation
can be used as measures of canonical TGFb signalling. To assess
the functional consequence of these TGFb receptor mutations, we
generated a panel of four TGFBR1 and ﬁve TGFBR2 mutant
expression plasmids from mutations identiﬁed in our original
targeted sequencing series. We assayed each mutant receptor for
functional activity in transient transfection reporter gene assays.
TGFBR1 expression plasmids were co-transfected into TGFBR1-
null mouse embryonic ﬁbroblasts30 and TGFBR2 expression
plasmids were co-transfected into TGFBR2-null T47D breast
cancer cells, in addition to the TGFb-responsive reporter
construct SMAD7-Promoter Luciferase31 (Fig. 4a and b,
respectively). Wild-type TGFb receptor expression elevated
reporter activity over empty vector controls, which was further
elevated by TGFb treatment (Fig. 4a,b). We conﬁrmed this
activity was dependent on intact SMAD binding elements in the
SMAD7 promoter (Supplementary Fig. 4a,b). The TGFBR1
mutants H331R and W277C, and all of the TGFBR2 mutants
(S474F, C486R, C96R, R2323W and A556T), failed to efﬁciently
activate the reporter gene, despite similar levels of expression of
the receptors, as assayed by western blotting (Fig. 4a,b). These
ﬁndings indicate that mutation of TGFBR1 and TGFBR2 in cSCC
frequently results in a loss of ability to activate canonical SMAD
signalling. To demonstrate corollary of these ﬁndings in primary
human tissue, we then established conditions to monitor
C-terminal PO4-SMAD3 levels using a C-terminal Ser433/
Ser435 PO4-SMAD3-speciﬁc antibody in cSCC by
immunohistochemistry (IHC) (Supplementary Fig. 5). We
measured PO4-SMAD3 activity in eight primary tumours
harbouring wild-type receptors and eight primary tumours
harbouring mutant TGFb receptors with a combined VAF of
420% (Supplementary Data 26). Wild-type tumours exhibited
readily detectable PO4-SMAD3 activity, whereas mutant tumours
showed signiﬁcantly reduced PO4-SMAD3 activity (Fig. 4c and
Supplementary Fig. 6), consistent with our observation that
mutation of TGFb receptors results in loss of canonical SMAD
signalling activity. Both wild-type and mutant tumours exhibited
heterogeneity of staining, consistent with our previous
observations that cSCC is heterogenous in nature6 and with the
VAFs observed in mutant tumours.
Finally, we used primary human cSCC cell lines to assess
whether TGFb receptor mutation results in a loss of TGFb
signalling. Exogenous treatment of normal human keratinocytes
(NHKs) with TGFb1 resulted in a dose-dependent decrease in cell
proliferation (Fig. 4d). The TGFBR2 mutant harbouring cell lines
SCCIC8 and SCCIC12 (Supplementary Data 3) failed to respond
to exogenous TGFb stimulation by either PO4-SMAD activation
(Supplementary Fig. 7) or by any effect on cell proliferation
(Fig. 4d). Co-transfecting these TGFBR2 mutant cells with either
empty vector, or wild-type TGFBR2 expression plasmids in
addition to a green ﬂuorescent protein (GFP) expression plasmid,
we measured cell proliferation in real time using Incucyte-Zoom
imager over 6 days. Cell proliferation of the GFPþ ve cells
indicated that cells expressing wild-type TGFBR2 proliferated at a
slower rate in the presence of exogenous TGFb (Fig. 4e). The
degree of inhibition was commensurate to the degree of
restoration of SMAD activity as measured using the multimerized
SMAD binding element reporter gene CAGA12-Luciferase32
(Supplementary Fig. 7c,d). These ﬁndings indicate that
re-expression of wild-type TGFBR2 restores canonical TGFb
signalling and proliferative inhibition, conﬁrming mutational loss
of TGFb tumour suppressive activity.
Matrix cells exhibit active TGFb signalling. Given this potential
aetiological loss of TGFb signalling, we sought to identify sites of
active TGFb signalling in normal skin, to gain insight into
the cellular origin of cSCC RAF inhibitor-induced lesions.
PO4-SMAD3 activity was barely detectable by IHC analysis in
normal human epidermis (Supplementary Fig. 8) but showed
strong immunoreactivity in the hair matrix zone of anagen hair
follicles (Fig. 5a and Supplementary Fig. 8). PO4-SMAD3 posi-
tivity was also detected in the hair matrix of anagen hair follicles
in mouse back skin (Fig. 5a). In anagen, the hair follicle transit-
amplifying (TA) cells are localized in the matrix and are positive
for Sonic hedgehog (SHH)11. Elegant studies by Blanpain and
colleagues11 have demonstrated these cells are unable to act as a
cell of origin for papilloma formation, even when both oncogenic
Kras and Tp53 were targeted. This suggests that these
PO4-SMAD3þ ve hair matrix cells are unlikely to be the cell of
origin for the rapid cSCC observed in humans following RAF
inhibitor treatment. To investigate this in the mouse, we tested
whether Tgfbr1 deletion could permit the transformation of TA
cells. RAF inhibitors stimulate paradoxical activation of the
MAPK pathway in cells with wild-type BRAF harbouring
upstream pathway activation, via mechanisms such as the
following: upregulated receptor tyrosine kinases, oncogenic
RAS via RAF dimer formation33–35 or relief of inhibitory auto-
phosphorylation36. Circumventing pharmacological enhance-
ment of MAPK signalling in the presence of mutated RAS, we
modelled hyperactivation of the MAPK pathway in the SHHþ ve
compartment by targeting downstream oncogenic BrafV600E and
oncogenic activation of KrasG12D. We crossed our previously
described LSL-BrafV600E mice37, which allow inducible expression
of BrafV600E from the endogenous Braf gene, with the ShhCREER
strain38. This permits tamoxifen-inducible activation of the Cre
recombinase in SHHþ ve cells. To assess the role of TGFb
signalling in the SHHþ ve cells, we then crossed these animals
with Tgfbr1ﬂ mice30 (Supplementary Fig. 9a,b). No tumours
formed in the skin of ShhCREER BrafV600E and ShhCREER
BrafV600E Tgfbr1ﬂ/þ mice (Fig. 5b and Supplementary
Fig. 10a,b). A small percentage of ShhCREER BrafV600E Tgfbr1ﬂ/
ﬂ mice developed minimally proliferative papillomatous lesions
(as evidenced by low level 5-bromodeoxyuridine (BrdU) staining)
mainly in the lips, but only at long latency (Fig. 5b and
Supplementary Fig. 10c). No mice developed cSCC. Mice failed to
develop any skin lesions following oncogenic activation of
KrasG12D with or without deletion of Tgfbr1 in this cell
compartment (Fig. 5c). Together, these studies indicate that the
SHHþ ve cells are unlikely to be the cell of origin for either rapid
onset vemurafenib-induced cSCC or sporadic cSCC.
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TGFb signalling is active in telogen bulge stem cells.
Approximately 90% of human hair follicles are present in the
anagen phase of the hair cycle with the remaining 10% existing in
catagen or the resting telogen phase. Analysis of human telogen
hair follicles revealed highly localized PO4-SMAD3 staining in the
bulge stem cells, characterized in part by Keratin 15 staining
(Fig. 6a). This pattern was recapitulated in mouse telogen hair
follicles (Fig. 6b), characterized by the expression of the stem
cell marker LGR5 (ref. 39). To investigate further, we used
the Lgr5-EGFP-Ires-CREERT2 knockin mouse (hereafter termed
Lgr5CREER), where the endogenous Lgr5 promoter controls
expression of enhanced GFP (EGFP) and the CREERT2 fusion
protein40. IHC analysis for GFP revealed a staining pattern
similar of that observed for PO4-SMAD3 (Fig. 6c). Furthermore,
co-immunoﬂuorescence revealed LGR5þ ve cells (stained for
EGFP) are highly enriched for both PO4-SMAD3 and TGFBR1
(Fig. 6d and Supplementary Fig. 11).
Recent studies indicate that the dermal papilla may provide a
source of TGFb2, activating SMAD signalling in overlying
hair germ stem cells41. We sorted epithelial EGFP-positive
LGR5þ ve stem cells from murine back skin. Quantitative
reverse-transcriptase PCR (qRT–PCR) analysis revealed
LGR5þ ve cells express enhanced levels of Tgfbr1, Tgfb1 and
Tgfb3 messenger RNA when compared with LGR5 ve cells, with
negligible amounts of Tgfb2 (Fig. 6e). Expression of Tgfbr2 was
readily detected in GFPþ ve and GFP ve compartments (Fig. 6e).
This indicates enriched autocrine TGFb signalling in the
LGR5þ ve compartment. We observed high levels of the TGFb
target gene Smad7 (ref. 42) in LGR5þ ve cells (Fig. 6e). Together,
these ﬁndings indicate that autocrine TGFb signalling is highly
localized to the LGR5þ ve hair follicle bulge stem cells in the
mouse and the Keratin 15þ ve hair follicle bulge stem cells in
humans, and that this cell compartment may give rise to both
vemurafenib-induced and sporadic cSCC.
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Rapid cSCC formation from Lgr5þ ve stem cells. To investigate
the consequence of hyperactivation of the MAPK pathway cou-
pled with ablation of TGFb signalling in LGR5þ ve stem cells, we
crossed the Lgr5CREER mice with the LSL-BrafV600E mice
(Supplementary Fig. 9c), or LSL-KrasG12D mice and Tgfbr1ﬂ mice
(Supplementary Fig. 9d). Loss of TGFb signalling alone was not
sufﬁcient to initiate tumorigenesis (Fig. 7a). Targeted activation of
BRAF to LGR5þ ve cells resulted in decreased survival, with all
mice killed 300 days post induction of the transgene by injection
of tamoxifen (median survival 276 days). Although 6 out of 14
mice succumbed to adrenal tumours, 50% of these mice presented
with papillomas consistent with LGR5 expression in murine skin
(Fig. 7a,c). However, the long latency period suggests Braf
mutation requires additional events to facilitate papilloma
development. The combined targeted inactivation of one allele of
Tgfbr1 reduced survival (median survival 231 days) and enhanced
both the number of mice with skin lesions and the number
of lesions per mouse (Fig. 7a,c and Supplementary Fig. 12a).
Inactivation of both Tgfbr1 alleles signiﬁcantly increased the
number of tumours per mouse and dramatically shortened both
skin tumour-free survival (all mice developing skin lesions within
63 days of induction) and overall survival (median survival 51
days) (Fig. 7a,c and Supplementary Fig. 12a). Phenotypically,
these lesions appeared as differentiated papillomas in Tgfbr1 wild-
type and heterozygous mice (Fig. 7c–e and Supplementary
Fig. 12b). Remarkably, in the homozygous Tgfbr1ﬂ/ﬂ mice,
tumours appeared as ulcerative cSCC (Fig. 7c and Supplementary
Fig. 12b). Elegant work by the laboratories of Blanpain and
colleagues11, and Jensen and colleagues10 have shown when Kras
is targeted to skin stem cells, there is long latency to papilloma
formation (similar to the BrafV600E allele described here) and
most of these lesions form around areas associated with
wounding. Targeted activation of Kras alone mainly failed to
produce skin lesions; however, when we targeted inactivation of
both alleles of Tgfbr1 and the KrasG12D mutation to the LGR5þ ve
compartment, mice developed rapid cSCC with kinetics compa-
rable to BrafV600E mice (Fig. 7b,c). In addition, Keratin 1 (Fig. 7d)
and Keratin 5 staining (Fig. 7e) revealed that cSCC lesions in both
the Braf and Kras mice are poorly differentiated cSCC.
Importantly, these lesions were highly proliferative
(Supplementary Fig. 12c) and never progressed via a papillo-
matous stage, recapitulating the rapid cSCC onset observed in
humans12,13. PO4-SMAD3 activity exhibited a dose-dependent
reduction in tumours isolated from these mice, indicating loss of
TGFb signalling (Supplementary Fig. 12d,e). qRT–PCR analysis
of these tumours revealed loss of Tgfbr1 expression (Supple-
mentary Fig. 12f) without any signiﬁcant change in ligand mRNA
expression (Supplementary Fig. 13).
Skin tissue compartmentalization has been recently proposed
as a mechanism involved in tissue maintenance10. To test whether
Tgfbr1 deletion perturbed such compartmentalization, we lineage
traced LGR5þ ve cells by intercrossing Lgr5CreER with the
RosaLSL-RFP reporter mice (Supplementary Fig. 9e). We
observed that red ﬂuorescent protein (RFP)-positive cells were
conﬁned to the hair follicle39 and were never detected in the
sebaceous gland, or interfollicular epidermis regions of Lgr5CreER
BrafV600E or Lgr5CreER BrafV600ETgfbr1ﬂ/þ mice, at early time
points post induction (Supplementary Fig. 14). The cSCC arising
within Lgr5CreER BrafV600ETgfbr1ﬂ/ﬂ mice were fully recombined
and RFP positive. In the normal skin comparator for these
tumours, but also at earlier time points, the LGR5þ ve cells and
their progeny were localized in their normal compartment
(Supplementary Fig. 14). These results indicate that
perturbation of TGFb signalling is insufﬁcient to disrupt
compartmentalization, but acts as a tumour suppressor in
LGR5þ ve stem cells.
Given the infrequent coincident activation of RAS genes and
mutational inactivation of TGFb receptors in sporadic cSCC, we
ﬁnally sought to model this disease by inactivating Tp53 function
coupled with deletion of Tgfbr1 in LGR5þ ve cells (Supplementary
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Fig. 9f). Knockin of mutant Tp53 (R172H) coupled with deletion
of the wild-type allele had no discernible phenotype (Fig. 8a).
Heterozygous knockin or deletion of Tp53 coupled with
homozygous deletion of Tgfbr1 resulted in the emergence of skin
tumours in a few mice (30% and 20%, respectively) with long
latency. Combined knockin of mutant Tp53 with deletion of the
wild-type allele of Tp53 coupled with deletion of Tgfbr1 resulted
in skin tumour development in 81% of mice with increased
tumour number at a shorter latency (Fig. 8a,b). These tumours
exhibited loss of differentiation expressing low levels of Keratin 1
and higher levels of Keratin 5 (Fig. 8c).
Discussion
Recent studies have revealed an exceptionally high mutation
burden (50 mutations per megabase of DNA6) in cSCC6,16,17.
This rate is second only to that of the commonest skin
malignancy basal cell carcinoma43. This translates to potentially
thousands of mutations per tumour, providing a particular
challenge in identifying driver mutations. This challenge is
further compounded by varying efﬁciencies in deep-sequencing
technologies and profound tumour heterogeneity2,6,44,45. Our
studies here reveal that targeted deep sequencing using ﬂuidigm
PCR ampliﬁcation and Roche 454 pyrosequencing can provide a
robust platform to identify mutations in NOTCH1, NOTCH2
(ref. 6), TGFBR1 and TGFBR2 genes. This approach has also
implicated alterations of NOTCH, TP53 and RAS in cSCC
tumour development6,46. We further these studies by revealing
mutation of TGFb receptors in 43% of sporadic human cSCC and
28% of vemurafenib-induced skin lesions (Fig. 1). The prevalent
tumour-initiating event in cSCC is ultraviolet-induced damage,
which manifests as C-T and G-A transitions39. Approximately
68% of all nucleotide changes observed in our cSCC samples
present with this signature6. Analysis of mutational signatures in
TGFb receptors reveals that 42% conform to an ultraviolet
signature (Fig. 3b and Supplementary Data 13). This ﬁgure
increases to 56.1% when scored as possibly damaging events via
protein function prediction programmes (Fig. 3d and
Supplementary Data 24). This indicates that ultraviolet damage
may also be responsible for inactivation of TGFb receptors.
Mutation prediction programmes scored 53.5% of TGFBR1 and
71.1% of TGFBR2 receptor mutants as damaging, indicating
thatB20% of cSCC harbour TGFb receptor inactivation (Supple-
mentary Data 15 and 16, and Fig. 3c). Subsequent functional
analysis of four TGFBR1 mutants and ﬁve TGFBR2 mutants
indicated that half of the TGFBR1 mutants and all ﬁve TGFBR2
mutants were loss of function for canonical Smad signalling, and
that tumours harbouring TGFb receptor mutations had reduced
PO4-SMAD3 activity (Fig. 4). Restoration of TGFBR2 expression
to TGFBR2-null cell lines restricted cell proliferation (Fig. 4).
Taken together, these ﬁndings indicate that loss of TGFb tumour
suppressor function is a common event in cSCC.
The assessment of VAFs provides an indication of the clonality
of tumours and aids the potential identiﬁcation of early driver
mutations during tumour development2. We ranked mutational
events by potential order of occurrence in the seven genes we
have previsouly implicated in cSCC development and TGFb
receptors by measurement of VAF (Supplementary Data 15 and
16). These analyses indicate that potentially damaging mutations
in TGFBR1 occur early in 25% of tumours harbouring these
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12493
10 NATURE COMMUNICATIONS | 7:12493 | DOI: 10.1038/ncomms12493 | www.nature.com/naturecommunications
mutations and in 42% of tumours harbouring potentially
damaging TGFBR2 mutations. Although this analysis is limited
to the 9 genes studied in-depth here (but importantly including
NOTCH genes previously identiﬁed as gatekeeper mutations in
cSCC6), 11 samples exhibited TGFb receptor mutations with the
highest VAF, indicating that this could be an initiating event in
the development of cSCC. Strong support for this hypothesis
comes from ABSOLUTE clonality analysis of our WES samples,
which revealed that 7/8 TGFb receptor mutations were clonal and
represent probable driver events in these lesions.
Several of our samples display VAFs of 10–20% for the TGFb
receptors, which is not too dissimilar to the VAFs of the other
known cSCC tumour suppressors studied here, and probably
reﬂects the heterogeneous nature of cSCC. It is however an
intriguing possibility that in some cases low TGFb receptor VAF
may reﬂect spontaneous regression of TGFb receptor mutant
clones as observed in multiple self-healing squamous epithelioma
patients who harbour germline mutations in TGFBR1 (ref. 47).
TGFb signalling has been demonstrated to play both positive and
negative roles in cSCC development in various mouse models48
acting to limit tumour cell proliferation, and also to promote
tumour-initiating capacity and drug resistance49. Effects are
dependent on the timing of aberrant TGFb signalling and the
cooperating oncogenic driving events (reviewed in refs 48,50–52).
We provide evidence that a dose-dependent loss of TGFb
signalling drives tumour progression, emphasizing its role as a
major tumour suppressor in the skin. Although the cell of origin
in cSCC in humans remains poorly deﬁned3, our observations
indicate that tumours can initiate efﬁciently and rapidly from
LGR5þ ve stem cells compared with TA cells, and mutational
modulation of two signalling pathways within this cellular
compartment is sufﬁcient to drive rapid progression directly to
carcinoma, without the need for protracted tumour evolution.
The kinetics of this event mimic exactly that observed during
development of cutaneous lesions in RAF inhibitor-treated
patients12,13. Intriguingly this rapid process requires MAPK
pathway activation as targeted intereference with Tp53 function
coupled with Tgfbr1 loss results in the development of skin
tumours with long latency. Importantly, our studies revealed
highly localized TGFb signalling in Keratin 15þ ve bulge stem
cells in human telogen hair follicles, mirrored exquisitly the
location of speciﬁc autocrine TGFb signalling activity identiﬁed
in LGR5þ ve bulge stem cells of murine telogen hair follicles. It
has been proposed that stem cell quiescence acts as a tumour
suppresive mechanism in murine skin, and that LGR5þ ve stem
cells are refractory to oncogenic transformation53. Our data
clearly indicate that oncogenic activation of the RAS/RAF/MAPK
pathway, or p53 modulation, coupled with loss of TGFb
signalling, is capable of leading to tumour development from
this compartment. As we demonstrate that mutational
inactivation of TGFb receptors is a frequent event in human
cSCC, and that TGFb signalling is highly localized to stem cells in
normal skin, we propose that these cells represent a cell of origin
for human cSCC. It remains possible that loss of TGFb signalling
may also contribute to cSCC development from other cell
compartments in the skin and this warrants further investigation.
Our data, both in human and mice, indicate that TGFb
signalling inactivation can be an initiating event in sporadic
cSCC. This is clearly the case in multiple self-healing squamous
epithelioma where germline loss-of-function mutations in
TGFBR1 have been identiﬁed as the underlying genetic lesion47.
We speculate that activation of the RAS/RAF/MAPK pathway, or
p53 modulation, may be a cooperating event in the development
of this disease, and that these tumours may originate from the
bulge stem cell compartment. TGFb signalling inactivation may
also occur following the acquisition of other driving mutational
events and act as a limiting factor for tumour development.
Intriguingly, initial clinical trials targeting systemic TGFb
inhibition with GC1008 (a pan-TGFb neutralizing antibody)
have also reported the occurrence of spontaneous cSCC as a side
effect54. This provides further compelling support for the tumour
suppressive role of TGFb in skin carcinogenesis.
Methods
Samples. Ethical approval for this investigation was obtained from the East
London and City Health Authority and the Tayside Tissue bank local ethics
committee, and the study was conducted according to the Declaration of Helsinki
Principles. All patients participating in this study were from dermatology and
plastic surgery units in the United Kingdom and all provided written, informed
consent. Punch biopsies of cSCC tissue were collected and processed as previously
reported6. NHKs were isolated from normal skin samples according to previously
published protocols55. Human tumour cell lines SCCIC1, SCCIC4, SCCIC8,
SCCIC15, SCCIC12, SCCIC18, SCCIC19, SCCIC21, SCCT1, SCCT2, SCCT6,
SCCT8, PM1, MET1, MET4, SCCT9, SCCT10, SCCT11, RDEBSCC2, RDEBSCC3,
RDEBSCC4 and NTERT cells were established by our laboratories and were
cultured as described15. TGFBR1-null MEFs30 and T47D cells (ATCC) were
maintained in DMEM and RPMI medium supplemented with 10% FCS,
respectively. Mycoplasma contamination checks were carried out on all cultures as
routine and all lines were conﬁrmed mycoplasma negative.
454 Sequencing. TGFBR1 and TGFBR2 primers were designed and validated by
Fluidigm (Fluidigm Corporation, San Francisco, CA) as per recommended
guidelines for Roche Titanium sequencing (Roche, Mannheim, Germany). Primers
for NOTCH1, NOTCH2, TP53, CDKN2A, HRAS, KRAS and NRAS were previously
described6 and all primer sequences are listed in Supplementary Data 27. Each
primer included sample-speciﬁc Fluidigm 454 barcode primer and adapter
sequences. Sequencing was performed in the same manner as our previous study56.
Brieﬂy, for thermal cycling a Fluidigm FC1 Cycler was used. The libraries were
normalized and pooled before puriﬁcation using Agencourt AMPure XP system
(Beckman, UK). Library components were clonally ampliﬁed utilising the GSJunior
emPCR Lib-A Kit (Roche) by inputting one molecule of library DNA per capture
bead. Pyrosequencing was done using the GS Junior system (Roche/454 Life
Sciences).
454 Variant analyses. Variant analysis was performed as previously described6.
Brieﬂy, reads were mapped to the hg19 build of the human genome using LASTZ
via the public GALAXY instance and ﬁltered to exclude those mapping to o100
loci using tools available through GALAXY.
Coding variants and splice site detection. Pileup ﬁles were generated and ﬁltered
using SAMTools57. Variants present in a single read or o10% of the total reads
were excluded using a custom java programme available from https://github.com/
mattsouth/laszt-variant-ﬁlter (last accessed 6 May 2013). Coding variants were
called against the RefSeq gene list using the amino acid tool via the public
GALAXY instance. Variants present in o3 reads were excluded. Variants present
in 41 independent sample and adjacent to a homopolymer 43 bases were
excluded, unless present in COSMIC58. Variants present in 430 samples were
excluded, unless present in COSMIC. All variants present in the exome variant
server database (http://evs.gs.washington.edu/EVS/) were excluded, unless
present in COSMIC. Splice sites were called from the pileup variant list if
present in 44 reads and within 2 bases of Refseq coding sequence using
Excel (Microsoft Inc., CA).
WES data analysis. Twenty previously published cSCC whole exomes6 were re-
analysed with the addition of ten new cSCC whole exomes with the overall mean
coverage of 63 (Supplementary Table 4), using a previous pipeline59. SNVs and
short indels were identiﬁed using the Strelka pipeline60 with a minimum coverage
of ten reads at the targeted sites. Annotation of somatic variants was performed
using the Oncotator tool61. Mutations in our targeted genes were further identiﬁed
across the 30 cSCC WES samples.
Copy number analysis using WES data. Two independent approaches were
applied. First, to generate SNP and indel variant genotyping information, the
tumour-normal pair was processed together against the reference genome using the
VarScan2 germline variants calling method mpileup2cns62. The minimum
coverage for identiﬁed sites was ten reads for both tumour and normal. Next, the
logR and BAF (B-allele frequency) ﬁles were created based on the tumour-normal
pair genotyping information, with the depth information normalized by dividing
the depth of each variant by the median depth across all variants. The ASCAT R
packages63 were then used to perform allele-speciﬁc copy number analysis, to
identify copy number aberrations and loss-of-heterozygosity regions. The second
approach was based on number of reads aligned to each exon between the tumour
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12493 ARTICLE
NATURE COMMUNICATIONS | 7:12493 | DOI: 10.1038/ncomms12493 | www.nature.com/naturecommunications 11
and normal pair. VarScan2 copy number calling method was ﬁrst applied. Raw
copy number calls were adjusted as previously reported64. Finally, results from the
two approaches were cross-compared, to produce the ﬁnal copy number
aberrations and acquired uniparental disomy calls for targeted genes.
Identiﬁcation of potential cancer drivers and signiﬁcantly mutated pathways.
Based on all mutations identiﬁed from the 30 cSCC WES data set, we used the
IntOGen platform19 to identify signiﬁcantly mutated genes and pathways, based on
the signiﬁcance (P-value) of the FM bias (that is, the bias towards the accumulation
of mutations with high functional impact). The signiﬁcantly mutated signalling
pathways (based on the IntOGen Oncodrive-fm functional impact bias, FM bias
Po0.05) were further selected (Supplementary Data 10). MutsigCV18 was also
used to detect signiﬁcant genes with point mutations above the background
mutation rate.
Estimating the clonality of mutations. For the somatic mutations of TGFBR1/2,
TP53, CDKN2A, NOTCH1/2 and RAS genes identiﬁed by WES (Supplementary
Data 7), we further classiﬁed them as clonal or subclonal on the basis of the
posterior probability that the cancer cell fraction exceeded 0.95 using ABSO-
LUTE20. Numbers of reads supporting the reference and alternative alleles were
extracted and the copy number segmentation ﬁles were generated based on the
DNAcopy CBS segments using WES data. Mutations with the somatic clonal
probability 40.5 were classiﬁed as clonal with high conﬁdence. Those mutations
with clonal probability40.25 but with very small subclonal probability scores were
also called clonal (Supplementary Data 12). Tumour purity and ploidy were also
estimated (Supplementary Data 11). For samples with TGFBR1/2mutations, cancer
cell fractions for TGFBR1/2 were further compared with those for other genes, to
determine the clonality orders.
Functional prediction of mutations. A combination of four approaches were used
to predict the functional impact of identiﬁed mutations by targeted sequencing,
(i) SIFT21, which uses sequence homology and protein conservation to predict the
effects of all possible substitutions at each position in the protein sequence; (ii)
PolyPhen-2 (ref. 22), which predicts possible functional impact of an amino acid
substitution on the structure and function level using physical and comparative
considerations; (iii) Provean23, which predicts the damaging effects of SNVs and
indels using a versatile alignment-based score; and (iv) Mutation Assessor24, which
measures the functional impact scores for amino acid residue changes using
evolutionary conservation patterns derived from aligned families and sub-families
of sequence homologues within and between species. Mutations predicted as
functional damaging by at least two of the four approaches were classiﬁed being
potentially damaging/deleterious.
In vivo analyses. All experiments were performed under the UK Home Ofﬁce
guidelines. Mice were segregating for C57BL6J and S129 background. Alleles used
throughout this study were: Lgr5-cre-ERT2(ref. 40), ShhCreER (ref. 38), BrafV600E
(ref. 37), KrasG12D (ref. 65), Tgfbr1ﬂ30, RosaLSL-RFP (ref. 66), Tp53ﬂ (ref. 67) and
Tp53R172H (ref. 68). A mix of males and females were used. Recombination in the
Lgr5-cre-ERT2 mouse model was induced with one intraperitoneal injection of 3mg
Tamoxifen (Sigma) followed by one injection of 2mg Tamoxifen for 3 days. Mice
were induced post 7 weeks of age. Recombination in the ShhCreER mouse model
was induced with one intraperitoneal injection of 2.5mg Tamoxifen. Mice were
induced post 28 days of age. For proliferation analysis, mice were injected with
250ml of BrdU (Amersham Biosciences) 2 h before being sampled.
FACS analysis. Epidermis was prepared as previously described69. Brieﬂy, fat was
scraped from the mouse back and left at 37 C in a dish (dermis down) in 0.25% of
Trypsin/EDTA (Invitrogen, Carlsbad, CA) for 90min. Epidermis was removed
using a scalpel and dissociated by pipetting. Cells were ﬁltered through a 40 mm
strainer, centrifuged at 250 g for 5min and washed with PE (PBS/EDTA). Cells
were washed with 0.1% BSA/PE, centrifuged at 250 g for 5min and used for
Lgr5-GFP sorting.
Immunohistochemistry. IHC was performed on formalin-ﬁxed skin sections.
Standard IHC techniques were used throughout this study. Primary antibodies
were as follows: TGFBR1 (Santa Cruz, V22, 1:100), PO4-SMAD3 (Abcam, EP823Y,
(52903), 1:50), GFP (Abgent, 168AT1211, 1:100), Keratin 1 (Covance, AF109,
1:1,000), Keratin 5 (Covance, AF138, 1:4,000), Keratin 15 (Abcam, 80522
(LHK15), 1:1,000), KI67 (Thermo, RM-9106-S) and BrdU (BD Biosciences,
347580, 1:200). Mouse PO4-SMAD3 score was performed in a blinded manner. For
each antibody, staining was performed on at least three mice of each genotype and
at least six sections of normal human skin. Representative images are shown for
each staining. PO4-SMAD3 antibody was optimized for IHC use using formalin-
ﬁxed parafﬁn-embedded SCCIC4 cells treated with and without recombinant
TGFb1 or the TGFBR1 kinase inhibitor SB-431542 (ref. 70) (Supplementary
Fig. 5). PO4-SMAD3 IHC scoring was performed in a blinded manner using the
histoscore method.
RNA isolation and quantitative PCR. RNA was isolated using a Qiagen RNeasy
Mini Kit (Qiagen, Crawly, West Sussex, UK) according to the manufacturer’s
instructions. DNA-free kit (Ambion/Applied Biosystems, Warrington, UK) was
used to remove genomic DNA contamination according to the manufacturer’s
instructions. One microgram of RNA was reverse transcribed to complementary
DNA using a DyNAmo SYBR Green 2-step quantitative PCR kit (Finnzymes,
Espoo, Finland) in a reaction volume of 20 ml. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used to normalize for differences in RNA input.
qRT–PCR primers. qRT–PCR primers were as follows. mTgfbr1 F-50-TGCCATA
ACCGCACTGTCA-30 , mTgfbr1 R-50-AATGAAAGGGCGATCTAGTGATG-30;
mTgfbr2 F-50-CCGGAAGTTCTAGAATCCAG-30 , mTgfbr2 R-50-TAATCCTTC
ACTTCTCCCAC-30 ; mTgfb1 F-50-AGCCCGAAGCGGACTACTAT-30, mTgfb1
R-50-TTCCACATGTTGCTCCACAC-30; mTgfb2 F-50-TTTAAGAGGGATCTT
GGATGGA-30, mTgfb2 R-50-AGAATGGTCAGTGGTTCCAGAT-30 ; mTgfb3
F-50-CGCACAGAGCAGAGAATTGA-30 , mTgfb3 R-50-GTGACATGGACAG
TGGATGC-30 ; mSmad7 F-50-TCAAGAGGCTGTGTTGCTGT-30 , mSmad7
R-50-TGGGTATCTGGAGTAAGGAGGA-30; and mGapdh F-50-GAAGGCCG
GGGCCCACTTGA-30 , mGapdh R-50-CTGGGTGGCAGTGATGGCATGG-30 .
Western blotting. Cells were lysed directly in 4 SDS sample buffer at 60–80%
conﬂuence. Lysates were subjected to standard SDS–PAGE. Bands were detected
using enhanced chemiluminescence solution (Amersham). Secondary antibodies
used throughout were horseradish peroxidase-conjugated polyclonal goat anti-
mouse Ig (Dako, P0448, 1:2,000) and horseradish peroxidase-conjugated polyclonal
goat anti-rabbit Ig (Dako, P0260, 1:2,000). Primary antibodies were PO4-SMAD3
(Abcam, 52903, 1:1,000), SMAD3 (Cell Signaling, 9523, 1:1,000), TGFBR1
(Santa Cruz, 398 (V22), 1:500) and TGFBR2 (Santa Cruz, 17792, (E6), 1:500). For
TGFBR2 western blottings, lysates were prepared directly from transfected cells
using the Dual-luciferase cell lysis buffer (Promega, UK). For TGFBR1 western
blottings, parallel transfections to the luciferase assays were performed and samples
were lysed directly in 4 SDS sample buffer. Original uncropped western blot
scans are also provided (Supplementary Fig. 15).
Plasmids. The full-length wild-type human TGFBR1 and pathogenic mutants,
ampliﬁed with BglII/NotI restriction sites, were shuttled into pCMV5 mammalian
cell expression vectors onto the BamHI/NotI sites. The full-length wild-type
human TGFBR2 and pathogenic mutants were sub-cloned into pCMV5 using the
BamHI/NotI restriction sites. Site-directed mutagenesis was carried out using the
QuickChange method (Stratagene) but substituting the Taq with KOD Hot Start
DNA polymerase (Novagen). All DNA constructs were veriﬁed by DNA sequen-
cing (by the DNA Sequencing Service at University of Dundee; www.dnaseq.co.uk).
GFP expression plasmid was from Amaxa.
Transient transfection analysis. All transfections were performed in 24-well
format in biological triplicate using LipofectAMINE 2000 (Invitrogen) according to
the manufacturer’s instructions. Cells were transfected overnight with 100 ng of
reporter gene (SMAD7-Promoter Luciferase or CAGA12-Luciferase) and 10 ng of
internal Renilla luciferase control (pRL-TK, E2241, Promega) with empty vector
(pCMV5, 211175, Stratagene), wild-type or mutant TGFb receptor plasmids (range
150–300 ng). Recombinant human TGFb1 (Peprotech) was dissolved in 4mM
HCL/1mgml 1 BSA and used at ﬁnal concentration of 5 ngml 1, and cells were
treated for 4 h before harvest. Luciferase activities were measured using the Dual
Luciferase assay (Promega) and ﬁreﬂy luciferase activity was normalized to Renilla
luciferase activity.
Cell proliferation assays. Cells were seeded at a density of 500–1,000 cells per
well of 96-well plates in keratinocyte media (RMþ ) without growth factors and
incubated overnight. Cells were fed 50 ml of medium supplemented with treatment
and controls every 2 days until harvest. All cultures were performed in sextuplet
(n¼ 6). Cells were assayed for proliferation using the CellTitreGlo Luminescent
Cell Viability assay (NHKs) as per the manufacturer’s instructions (Promega;
luminesence was measured on a Berthold Orion II microplate luminometer) or
IncucyteZoom Live cell imager.
Data availability. The WES data for the 30 samples have been deposited in the
European Genome-phenome Archive under accession code EGAS00001001892.
The authors declare that all other relevant data supporting the ﬁndings
of this study are available within the article and its Supplementary Information
ﬁles. Additional information can be obtained from the corresponding authors
(G.J.I. and O.J.S.).
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